

# Novel assays for assessing protein-protein interactions in Alzheimers disease

<https://www.neurodegenerationresearch.eu/survey/novel-assays-for-assessing-protein-protein-interactions-in-alzheimers-disease/>

## Principal Investigators

BUTT, TAUSEEF R.

## Institution

LIFESENSORS, INC.

## Contact information of lead PI

### Country

USA

## Title of project or programme

Novel assays for assessing protein-protein interactions in Alzheimers disease

## Source of funding information

NIH (NIA)

## Total sum awarded (Euro)

206122.9358

## Start date of award

30/09/2016

## Total duration of award in years

1

## Keywords

Acquired Cognitive Impairment... Aging... Alzheimer's Disease... Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)... Bioengineering... Biotechnology... Brain Disorders... Dementia... Neurodegenerative... Neurosciences

## Research Abstract

Abstract Cell-based assays more closely mimic biology than direct inhibition studies. Therefore, drug discovery companies are increasingly utilizing cellular screening assays. Current reporter systems are unable to reliably measure in-cell transient protein-protein interactions. Furthermore, many are based upon split enzyme systems, which require long incubation steps,

are not real-time and are typically low throughput. In order to improve on these existing technologies, we will develop a split SUMOstar system engineered to contain a tetracysteine recognition motif for a biarsenical-based fluorophores. There are several advantages for using split a SUMOstar fluorescent reporter system, including relatively small fusions (~6 Kda) to the target proteins of interest, lower non-specific interaction with native proteins and the ability to take real-time measurements in high-throughput applications. Furthermore, using structural based mutagenesis, we can engineer the kinetics and binding affinity of the split SUMO interaction, allowing us to fine-tune the reporter assay to measure transient protein-protein interactions.

**Further information available at:**

**Types:**

Investments < €500k

**Member States:**

United States of America

**Diseases:**

N/A

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A